Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. - Rousset M; Dutriaux C; Bosco-Lévy P; Prey S; Pham-Ledard A; Dousset L; Gérard E; Bouchet S; Canal-Raffin M; Titier K; Molimard M (Clinica chimica acta; international journal of clinical chemistry, 2017)